[Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches]

Med Clin (Barc). 2004 Jan 24;122(2):57-9. doi: 10.1016/s0025-7753(04)74140-8.
[Article in Spanish]

Abstract

Background and objective: We aimed to compare treatment adherence and toxicity of isoniazide (H) (6 months) compared with rifampicine (R) + pirazinamide (Z) (2 months) in homeless patients in latent tuberculous infection (LTBI).

Patients and method: Randomized and controlled prospective study.

Results: We included 172 patients (116 males and 56 females) with an age average of 42.3 (12.8) years; 31 (18%) had recent conversion and 72 (41.8%) had some risk factor of hepatotoxicity. Both bivariate and multivariate analysis (p < 0.001; OR = 5.15 [2.34-11.35]) showed that the treatment was completed by 61.5% of patients administered the R+Z regimen, while it was completed only by 28.2% of those administered H for 6 months. Moreover, treatment was completed by 48.4% of Spanish or foreign patients with legal residence, while it was completed only by 28.6% of immigrant patients with no legal residence (p = 0.044 in bivariate analysis).

Conclusions: The R+Z regimen for 2 months as treatment of LTBI in homeless patients displays a higher adherence than H for 6 months. There were no differences in toxicity.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Ill-Housed Persons*
  • Isoniazid / administration & dosage
  • Isoniazid / therapeutic use
  • Male
  • Patient Compliance*
  • Prospective Studies
  • Pyrazinamide / administration & dosage
  • Pyrazinamide / therapeutic use*
  • Rifampin / administration & dosage
  • Rifampin / therapeutic use*
  • Tuberculosis / drug therapy*

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Isoniazid
  • Rifampin